

Joanna Gã³ra-Tybor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5471736/publications.pdf>

Version: 2024-02-01

71
papers

1,479
citations

361296

20
h-index

315616

38
g-index

77
all docs

77
docs citations

77
times ranked

1651
citing authors

#	ARTICLE	IF	CITATIONS
1	The Outcomes of Ponatinib Therapy in Patients With Chronic Myeloid Leukemia Resistant or Intolerant to Previous Tyrosine Kinase Inhibitors, Treated in Poland Within the Donation Program. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 405-415.	0.2	4
2	Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs. <i>Blood Advances</i> , 2022, 6, 5171-5183.	2.5	12
3	Do myeloproliferative neoplasms and multiple myeloma share the same genetic susceptibility loci?. <i>International Journal of Cancer</i> , 2021, 148, 1616-1624.	2.3	7
4	Azacitidine for relapse of acute myeloid leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation, multicenter PALG analysis. <i>European Journal of Haematology</i> , 2021, 107, 129-136.	1.1	4
5	Genetic polymorphisms associated with telomere length and risk of developing myeloproliferative neoplasms. <i>Blood Cancer Journal</i> , 2020, 10, 89.	2.8	20
6	A Multicenter Prospective Study on Efficacy and Safety of Ponatinib in Patients with Chronic Myeloid Leukemia Resistant or Intolerant to Previous Therapy: A 3-Year Report. <i>Blood</i> , 2020, 136, 40-41.	0.6	1
7	Antifungal management in adults and children with hematological malignancies or undergoing hematopoietic cell transplantation: recommendations of Polish Society of Hematology and Blood Transfusion, Polish Society of Pediatric Oncology and Hematology, and Polish Adult Leukemia Study Group. 2020. <i>Acta Haematologica Polonica</i> . 2020. 51. 60-72.	0.1	0
8	Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis: A Retrospective Analysis of 527 Patients From the Polish Adult Leukemia Group Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e283-e285.	0.2	5
9	Miejsce ruksolityny w leczeniu chorych na mielofibrozę™. <i>Hematologia</i> , 2018, 9, 90-99.	0.0	0
10	Leki wpływające na mechanizmy epigenetyczne w ostrej białaczce szpikowej. <i>Hematologia</i> , 2018, 9, 110-122.	0.0	0
11	Zaburzenia mechanizmów epigenetycznych w ostrej białaczce szpikowej. <i>Hematologia</i> , 2018, 9, 100-109.	0.0	0
12	Quality of Life and Adherence to Therapy in Patients With Chronic Myeloid Leukemia Treated With Nilotinib as a Second-Line Therapy: A Multicenter Prospective Observational Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 283-295.	0.2	12
13	Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors. <i>Medical Oncology</i> , 2017, 34, 104.	1.2	35
14	A multicenter prospective study on efficacy and safety of imatinib generics: A report from Polish Adult Leukemia Group imatinib generics registry. <i>American Journal of Hematology</i> , 2017, 92, E125-E128.	2.0	24
15	Limfocytarne zapalenie opon mózgowo-rdzeniowych w przebiegu dokonańowego leczenia liposomalną... cytarabiną... u chorego na ostrą... białaczkę™ limfoblastyczną... <i>Hematologia</i> , 2017, 8, 228-233.	0.0	1
16	Współistnienie dyskrazji komórek plazmatycznych i zespołu mielodysplastycznego – opisy przypadków w i przebiegu piśmiennictwa. <i>Hematologia</i> , 2017, 8, 144-151.	0.0	2
17	Ocena stanu odżywienia pacjentów z nowotworami układu krwiotwórczego i chłonnego za pomocą... skali PG-SGA. <i>Hematologia</i> , 2017, 8, 105-112.	0.0	0
18	Przeszczepienie allogeniczných krwiotwórczych komórek macierzystych w leczeniu chorych na mielofibrozę™. <i>Hematologia</i> , 2017, 8, 132-143.	0.0	0

#	ARTICLE	IF	CITATIONS
19	Zalecenia dotyczące oceny schorzeń, współistniejących u chorych na przewlekłą, białaczkę szpikową w procesie wyboru inhibitora kinaz tyrozynowych. <i>Acta Haematologica Polonica</i> , 2016, 47, 184-196.	0.1	1
20	Znaczenie prognostyczne minimalnej choroby resztkowej ocenianej metodami cytometrii przepływowej w ostrej białaczce szpikowej. <i>Hematologia</i> , 2016, 7, 97-107.	0.0	0
21	Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis: A Retrospective Analysis of 470 Patients from the Polish Adult Leukemia Group (PALG) Registry. <i>Blood</i> , 2016, 128, 1909-1909.	0.6	1
22	Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment. <i>Leukemia and Lymphoma</i> , 2015, 56, 2309-2314.	0.6	34
23	Clinical relevance of vascular endothelial growth factor type A (VEGFA) and VEGF receptor type 2 (VEGFR2) gene polymorphism in chronic lymphocytic leukemia. <i>Blood Cells, Molecules, and Diseases</i> , 2015, 54, 139-143.	0.6	10
24	Nowotwory mieloproliferacyjne i zespoły mielodysplastyczne – postępy w diagnostyce i terapii. <i>Hematologia</i> , 2015, 6, 70-76.	0.0	0
25	Long-term results of the Polish Adult Leukemia Group PALG-CLL2 phase III randomized study comparing cladribine-based combinations in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 606-610.	0.6	5
26	Impact of Drug Transporters ABCB1 and ABCG2 and Regulators of Xenobiotic Transport and Metabolism Pxr and CAR Gene Polymorphisms on Clinical Efficacy of Imatinib in Chronic Myeloid Leukemia (CML). <i>Blood</i> , 2014, 124, 5222-5222.	0.6	0
27	The Influence of Maltotriose-Modified Poly(propylene imine) Dendrimers on the Chronic Lymphocytic Leukemia Cells <i>in Vitro</i> : Dense Shell G4 PPI. <i>Molecular Pharmaceutics</i> , 2013, 10, 2490-2501.	2.3	32
28	Immune thrombocytopenia in patients with chronic lymphocytic leukemia treated with cladribine-based regimens or chlorambucil – follow-up of PALG-CLL randomized trials. <i>European Journal of Haematology</i> , 2013, 91, 1-9.	1.1	3
29	Real-Life Comparison Of Severe Vascular Events and Other Non-Hematological Complications In CML Patients Treated With Second Line Nilotinib Or Dasatinib. <i>Blood</i> , 2013, 122, 1491-1491.	0.6	3
30	Emerging Therapies in Chronic Myeloid Leukemia. <i>Current Cancer Drug Targets</i> , 2012, 12, 458-470.	0.8	12
31	Poor prognosis of Hodgkin variant of Richter transformation in chronic lymphocytic leukemia treated with cladribine. <i>British Journal of Haematology</i> , 2012, 158, 286-288.	1.2	20
32	Nanoparticles – a Novel Approach to Chronic Lymphocytic Leukemia Treatment?. <i>Blood</i> , 2012, 120, 4601-4601.	0.6	5
33	Dasatinib in the Treatment of Chronic Myeloid Leukemia. <i>Current Signal Transduction Therapy</i> , 2011, 6, 99-105.	0.3	0
34	Comparison of Cladribine Plus Cyclophosphamide With Fludarabine Plus Cyclophosphamide As First-Line Therapy for Chronic Lymphocytic Leukemia: A Phase III Randomized Study by the Polish Adult Leukemia Group (PALG-CLL3 Study). <i>Journal of Clinical Oncology</i> , 2010, 28, 1863-1869.	0.8	86
35	Prognostic value of the bone marrow microvessel density in progressive B-cell chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 1351-1353.	0.6	6
36	Clinical Relevance of Vascular Endothelial Growth Factor Type A (VEGFA) and VEGF Receptor Type 2 (VEGFR2) Gene Polymorphism In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 4467-4467.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion. <i>Cancer</i> , 2009, 115, 94-100.	2.0	26
38	Evaluation of circulating endothelial cells as noninvasive marker of angiogenesis in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 62-67.	0.6	20
39	Elevated plasma levels of the angiogenic tetrapeptide acetyl-ser-asp-lys-pro are found in some patients with hematologic malignancies. <i>Leukemia and Lymphoma</i> , 2009, 50, 2096-2097.	0.6	8
40	Targeted Drugs in Chronic Myeloid Leukemia. <i>Current Medicinal Chemistry</i> , 2008, 15, 3036-3051.	1.2	60
41	Randomized Comparison of Cladribine Plus Cyclophosphamide with Fludarabine Plus Cyclophosphamide in Untreated Patients with Chronic Lymphocytic Leukemia: Report of the Polish Adult Leukemia Group (PALG-CLL3).. <i>Blood</i> , 2008, 112, 2103-2103.	0.6	1
42	Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. <i>Blood</i> , 2007, 109, 3672-3675.	0.6	70
43	Influence of cladribine alone and in combination with cyclophosphamide or cyclophosphamide and mitoxantrone on bone marrow angiogenesis in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2007, 48, 1042-1044.	0.6	5
44	Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 1092-1101.	0.6	10
45	Circulating Endothelial Cells as Noninvasive Marker of Angiogenesis in Patients with Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2007, 110, 1124-1124.	0.6	0
46	Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). <i>Blood</i> , 2006, 108, 473-479.	0.6	119
47	Cladribine in Weekly Versus Daily Schedule for Untreated Active Hairy Cell Leukemia: Final Report of Polish Adult Leukemia Group (PALG) Prospective, Randomized, Multicenter Trial.. <i>Blood</i> , 2006, 108, 2485-2485.	0.6	6
48	Randomized Comparison of Cladribine Plus Cyclophosphamide with Fludarabine Plus Cyclophosphamide in Progressive Chronic Lymphocytic Leukemia: An Updated Report of Prospective PALG-CLL3 Study.. <i>Blood</i> , 2006, 108, 2826-2826.	0.6	1
49	Richter syndrome first manifesting as cutaneous B-cell lymphoma clonally distinct from primary B-cell chronic lymphocytic leukaemia. <i>British Journal of Dermatology</i> , 2005, 153, 833-837.	1.4	21
50	Circulating vascular endothelial growth factor (VEGF) and its soluble receptors in patients with chronic lymphocytic leukemia. <i>European Cytokine Network</i> , 2005, 16, 41-6.	1.1	24
51	Rituximab Followed by Cladribine in the Treatment of Heavily Pretreated Patients with Indolent Lymphoid Malignancies. <i>Leukemia and Lymphoma</i> , 2004, 45, 937-944.	0.6	29
52	Richter's Syndrome in the Brain First Manifested as an Ischaemic Stroke. <i>Leukemia and Lymphoma</i> , 2004, 45, 1261-1267.	0.6	13
53	Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine. <i>European Journal of Cancer</i> , 2004, 40, 383-389.	1.3	67
54	Cladribine Alone or in Combination with Cyclophosphamide or Cyclophosphamide and Mitoxantrone as First Line Treatment in Chronic Lymphocytic Leukemia: An Early Report of Prospective Randomized Study.. <i>Blood</i> , 2004, 104, 337-337.	0.6	4

#	ARTICLE	IF	CITATIONS
55	Randomized Comparison of Weekly Administration and Daily Courses of Cladribine in Patients with Hairy Cell Leukemia - Updated Results.. Blood, 2004, 104, 3478-3478.	0.6	3
56	The Effect of Subsequent Therapies in the Patients with Chronic Lymphocytic Leukemia Previously Treated with Cladribine and Prednisone or Chlorambucil and Prednisone in Randomized Studies.. Blood, 2004, 104, 4819-4819.	0.6	0
57	Coexistence of Chronic Lymphocytic Leukemia and Essential Thrombocythemia. Leukemia and Lymphoma, 2003, 44, 1425-1431.	0.6	11
58	Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia. Mediators of Inflammation, 2003, 12, 167-171.	1.4	21
59	Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment. European Journal of Haematology, 2002, 69, 27-36.	1.1	13
60	Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia. The Hematology Journal, 2002, 3, 244-250.	2.0	40
61	Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia. Leukemia, 2001, 15, 1510-1516.	3.3	35
62	Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies. European Journal of Haematology, 2001, 66, 188-194.	1.1	30
63	Combination Regimen of 2-Chlorodeoxyadenosine (Cladribine), Mitoxantrone and Dexamethasone (CMD) in the Treatment of Refractory and Recurrent Low Grade Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 1999, 32, 359-363.	0.6	24
64	The susceptibility of Philadelphia chromosome positive cells to FAS-mediated apoptosis is not linked to the tyrosine kinase activity of BCR-ABL. British Journal of Haematology, 1998, 103, 716-720.	1.2	13
65	The Presence of Typical and Atypical BCR-ABL Fusion Genes in Leukocytes of Normal Individuals: Biologic Significance and Implications for the Assessment of Minimal Residual Disease. Blood, 1998, 92, 3362-3367.	0.6	413
66	Activity of 2-chlorodeoxyadenosine (cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-hodgkin's lymphoma. Leukemia and Lymphoma, 1997, 26, 99-105.	0.6	24
67	Fulminant 2-Chlorodeoxyadenosine-Related Peripheral Neuropathy in a Patient with Paraneoplastic Neurological Syndrome Associated with Lymphoma. Leukemia and Lymphoma, 1996, 21, 343-346.	0.6	6
68	The influence of 2- chlorodeoxyadenosine in combination with tumour necrosis factor- $\hat{I}\pm$ or its mutein on murine leukaemias L1210 and P388. Mediators of Inflammation, 1995, 4, 205-208.	1.4	1
69	The Influence of 2-Chlorodeoxyadenosine (2-CdA) Alone and in Combination with Cyclophosphamide or Methotrexate on Normal and Leukemic Hematopoiesis. Advances in Experimental Medicine and Biology, 1995, 370, 129-130.	0.8	2
70	A comparison of the Antileukaemic Effects of Recombinant Human Tumour Necrosis Factor- $\hat{I}\pm$ and its Muteins on Leukaemia L1210 and Leukaemia P388 in Mice. Mediators of Inflammation, 1994, 3, 411-414.	1.4	2
71	The interaction of 2-chlorodeoxy adenosine (2-CDA) and interferon $\hat{I}\pm$ (IFN- $\hat{I}\pm$) on normal and myeloid leukemia hematopoiesis in vitro. Leukemia Research, 1994, 18, 275-281.	0.4	10